COVID-19 Update

Due to the global COVID-19 pandemic and rapidly evolving public health organization guidance pertaining to its response, PAINWeek has made the decision to postpone the Dallas PAINWeekEnd scheduled for May 2.

As you are undoubtedly aware, the Centers for Disease Control and Prevention (CDC) has recommended that in-person events comprising 50 or more attendees not be held for the next 8 weeks. Concurrently, various state and local authorities have begun directing the closure of bar, restaurant, and public service establishments in their jurisdictions. In view of the critical importance of these and other social distancing measures to attenuate the spread of infection and its impact on the healthcare system, we believe this postponement of our upcoming conferences is unavoidably necessary. A revised schedule for this conference will be developed and provided as soon as possible. Your registration will automatically transfer to the new date; however, you may request an immediate refund of your registration fee if you prefer.

If you made airline reservations, we recommend that you contact the airline to cancel. Most major carriers have added flexible change and cancellation policies. If you had plans to stay overnight, please contact the hotel directly to cancel your reservation.

The Westin Galleria Dallas will honor no-charge cancellation or changes (subject to availability and rate differences) of any existing reservation up to 24 hours prior to arrival. More details are available here.

We greatly regret the impact of this postponement on our attendees’ professional schedules and their interest in pain management education. As primary care practitioners, many of you are truly on the front lines of patient care in your communities, now more than ever in this uncertain time.

We are looking into adding more virtual and distance learning options. In the meantime, if you haven’t already done so, we recommend visiting the online education section of our website that includes articles, videos, interviews with thoughts leaders, and our PAINWeek Journal. We have also recently posted a webcourse entitled "Understanding and Addressing the Global Spread of the COVID-19 Infection: A Clinician's Guide" that is certified for 1-hour of CME/CE credit.

Please contact us with any questions or issues pertaining to your registration. Please accept our thanks for your understanding and support.

Saturday, May 2, 2020


    Coffee will be served.

  • Pain Management at Ground Zero

    West Virginia continues to lead the nation, and world, in drug overdoses, which makes one ponder what is being done at the “ground zero” of the opioid epidemic to save and improve lives. Where better than where it’s worst should some of the possible solutions come from? In 2016, an interprofessional panel of experts in pain management—ranging from medicine, osteopathy, nursing, pharmacy, dentistry; public health; the state PDMP; and representatives from insurance providers—was put together with aims of finding possible solutions. The West Virginia Safe & Effective Management of Pain (SEMP) Guidelines ( were developed to facilitate the shift of the best practices in pain management becoming the new standard of care. The SEMP Guidelines include 2 main components including the risk reduction strategy and the clinical treatment algorithms. Pain management algorithms are not available anywhere else in the entire world! So we would like to welcome you to “the West Virginia Way” and see just how the “wild and wonderful” state of West Virginia is approaching the opioid epidemic from a true ground zero. After all, if it works where it’s worst, how could it not help your state or your practice?

    • UAN: 0530-0000-20-043-L04-P
    • AANP Rx Hours: 0.00

    Breakfast will be served.

    *This session is not certified for credit.


  • Causalytics – You’re in Pain, and it’s All Your Fault

    Assessment, diagnosis, treatment plan formulation, implementation, and follow-up are processes familiar to clinicians and are the main drivers of safe and effective chronic pain treatment. However, many other things influence our clinical decision-making, including the continuing controversies about the role of opioid analgesics in the management of chronic pain, the “opioid epidemic” our nation faces today, and the fear of regulatory scrutiny just to name a few. Additionally, when formulating decisions about pain treatment, the subjective nature of chronic pain and determining the context of how pain is affecting a person’s life may often be challenging. What we might not be aware of is how other more subtle forces can potentially influence us and have a negative impact on the care we provide for patients—the things that we “bring into the examination room.” This session will focus on how things like precognitive thinking, implicit biases, explicit biases, impressions about patient characteristics and even their demographics may potentially alter our judgment and create disparity. Suggestions will be presented to help recognize and reflect about how we can make sure that the pain care we deliver is not compromised by these things we might not consider, even though they are there.

    • UAN: 0530-0000-20-041-L04-P
    • AANP Rx Hours: 0.10
  • Drugs, Documentation, and DEA: Improving Your Charting of Prescribing Rationale in 2020 and Beyond

    Overlooking the importance of carefully documenting the rationale for the use of a controlled medication can land a prescriber in hot water with their licensing board or the DEA. This course will focus on what it takes to move beyond the problems associated with both EMR and handwritten medical charts, and into the documentation of cogent notes signaling proper patient evaluation, including risk evaluation, rationale for the use of controlled medication, and ongoing encounters with the patient.

    • UAN: 0530-0000-20-027-L03-P
    • AANP Rx Hours: 0.00



    Lunch will be served.

    Sponsored by AstraZeneca-Daiichi Sankyo, Inc.

    *This session is not certified for credit.

  • Mirror Mirror on the Wall: Who's the FDA's Fairest ADF of All?

    Challenge accepted. Our country has made numerous strides in advancing patient care, and more particularly conducting efforts to ensure that lives within the national opioid crisis are saved and/or improved. One of those positive strides involves the FDA approval of abuse deterrent formulation (ADF) opioid medications, with the aim of preventing the transition from the misuse and/or abuse of prescription opioid medications to illicit (and possibly laced) diacetylmorphine (aka heroin). How do these formulations work, one might ask? Which ADF opioid medications are not only available on the us market, but also specifically approved as an ADF opioid medication? Are these ADFs really foolproof? Well, the street chemists of our country have already accepted the challenge to be knowledgeable on all of the above. Now it’s our turn as healthcare professionals to get up to speed on these risk reduction entities.

    • UAN: 0530-0000-20-042-L04-P
    • AANP Rx Hours: 0.80


    Refreshments will be served.

    *This session is not certified for credit.

  • The Other Opioid Crisis: Heroin and Fentanyl

    There is a significant amount of media, political, and public attention paid to the opioid crisis/opioid epidemic in the United States today. With the seemingly ever-increasing number of opioid-related overdoses and fatalities, there has been a feverish push by stakeholders to diminish the amount of opioids prescribed in order to help stem these worrisome trends. Unfortunately, there may be a lack of focus regarding the true definition and characterization of the opioid epidemic. There may also be a rush to judgment about the role of appropriately prescribed opioid analgesics in the addiction crisis we face today as well. This presentation will discuss the roles and statistics of both prescription and illicit opioids (namely heroin and fentanyl) in today’s “opioid overdose epidemic” with the intention of clarifying important differences and similarities between these competing epidemics including concerns and clinical considerations specific to each of them. Additionally, this program will examine and identify how these medications and drugs share potentially tragic adverse effect profiles in many cases. However, it is important for clinicians to make sure that appropriate chronic pain patients that may be candidates for opioid analgesic therapy aren’t penalized, and still get the treatment that they deserve.

    • UAN: 0530-0000-20-044-L04-P
    • AANP Rx Hours: 0.00
  • Through the Lens of Experts: Meaningful Risk Mitigation and Patient Education

    Those who have been on either side of a courtroom battle on chronic opioid therapy have seen experts and lawyers spend a great deal of time arguing about the extent and nature of risk mitigation and patient education necessary to demonstrate that the prescriber issued a valid controlled substance prescription. The focus of expert testimony is on whether the prescriber engaged in meaningful risk evaluation and monitoring practices, and whether the prescriber individualized medical care for the patient, based on specific history and behaviors as treatment went on. This course will use published medical expert testimony and common expert reports of illegal and insufficient risk mitigation and patient education. The main goal is to facilitate a prescriber's self-audit of risk mitigation practices and to help attendees improve documentation of risk mitigation protocols and patient education efforts. A proactive approach to meaningful risk mitigation is necessary for protecting patient access to quality pain care and creating a framework within which other practitioners may confidently assume care for patients when necessary, and demonstrating appropriate prescribing of chronic opioid therapy.

    • UAN: 0530-0000-20-035-L01-P
    • AANP Rx Hours: 0.00